APC-Placebo

BIOLOGICAL2 trials

Conditions

Hormone-Refractory Prostate CancerProstate Cancer

Phase 3

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

CompletedNCT00065442

DendreonProstate Cancer

Start: 2003-07-31End: 2009-01-31Updated: 2010-09-06

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer

CompletedNCT01133704

DendreonHormone-Refractory Prostate Cancer

Start: 2000-05-31End: 2005-05-31Updated: 2010-09-08

2025-03-014 citations

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

Clinical Cancer Research2023-04-1415 citations

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer2021-08-0162 citations

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

2020-02-2894 citations

A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2020-02-198 citations

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer

Cancer2019-09-0467 citations

Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience.

Journal of Clinical Oncology2019-05-20

Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB).

Journal of Clinical Oncology2019-03-011 citations

Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.

Journal of Clinical Oncology2019-03-011 citations

Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T).

Journal of Clinical Oncology2017-03-01

Boosting long-term immune responses to sipuleucel-T (sip-T) by retreatment of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2017-02-207 citations

Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).

Journal of Clinical Oncology2017-02-205 citations

Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).

Journal of Clinical Oncology2017-02-201 citations

Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T).

Journal of Clinical Oncology2016-05-20

The impact of age on sipuleucel-T-induced immune responses.

Journal of Clinical Oncology2015-05-20

Abstract 2542: Sipuleucel-T-induced immune response against secondary cancer antigens is associated with improved overall survival

Cancer Research2014-10-011 citations

A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T

Cancer Immunology Research2014-09-0552 citations

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

2014-06-2422 citations

PD27-04 SIPULEUCEL-T-INDUCED ANTIGEN SPREAD: IMMUNE RESPONSE TO PROSTATE-SPECIFIC ANTIGEN CORRELATES WITH IMPROVED OVERALL SURVIVAL

The Journal of Urology2014-03-282 citations

Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer.

Journal of Clinical Oncology2014-02-018 citations

1 more papers not shown

APC-Placebo

Sponsors

Conditions

Phase 3

Related Papers